[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100659868":3},{"organization":4,"outcomesModule":7,"designInfo":36,"detailedDescription":39,"studyPopulation":40,"armGroups":41,"interventions":47,"overallOfficials":35,"centralContacts":52,"locations":58,"responsibleParty":71,"collaborators":35,"id":75,"slug":76,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":35,"eligibilityCriteria":81,"healthyVolunteers":77,"sex":82,"minAge":83,"maxAge":35,"enrollmentInfo":84,"targetDuration":87,"studyType":88,"phases":35,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":94,"whyStopped":35,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"Chinese University of Hong Kong","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":35},[9],{"measure":10,"description":11,"timeFrame":12},"Difference in total number of symptomatic catheter-associated urinary tract infection (CAUTI) requiring hospital admission","By comparing the total number of symptomatic catheter-associated urinary tract infection (CAUTI) requiring hospital admission during the 6-month post-intervention period and the 6-month pre-intervention period.","6-month post-intervention period compared with the 6-month pre-intervention period",[14,17,20,23,26,29,32],{"measure":15,"description":16,"timeFrame":12},"Difference in total number of emergency department visits for suspected UTI or urosepsis","By comparing the total number of emergency department visits for suspected UTI or urosepsis during the 6-month post-intervention period and the 6-month pre-intervention period.",{"measure":18,"description":19,"timeFrame":12},"Difference in total number of antibiotic courses","By comparing the total number of antibiotic courses during the 6-month post-intervention period and the 6-month pre-intervention period.",{"measure":21,"description":22,"timeFrame":12},"Difference in total number of antibiotic days of therapy","By comparing the total number of antibiotic days of therapy during the 6-month post-intervention period and the 6-month pre-intervention period.",{"measure":24,"description":25,"timeFrame":12},"Difference in time to first CAUTI admission","By comparing the time to first catheter-associated urinary tract infection admission during the 6-month post-intervention period and the 6-month pre-intervention period.",{"measure":27,"description":28,"timeFrame":12},"Difference in total number of unplanned catheter changes or catheter blockage events","By comparing the total number of unplanned catheter changes or catheter blockage events during the 6-month post-intervention period and the 6-month pre-intervention period.",{"measure":30,"description":31,"timeFrame":12},"Difference in total number of all-cause hospital admissions","By comparing the total number of all-cause hospital admissions during the 6-month post-intervention period and the 6-month pre-intervention period.",{"measure":33,"description":34,"timeFrame":12},"Difference in total number of adverse events related to immunotherapy","By comparing the total number of adverse events related to immunotherapy during the 6-month post-intervention period and the 6-month pre-intervention period.",null,{"allocation":35,"interventionModel":35,"interventionModelDescription":35,"primaryPurpose":35,"observationalModel":37,"timePerspective":38,"maskingInfo":35},"CASE_ONLY","PROSPECTIVE","The aim of the study is to prospectively evaluate Uromune as a potential non-antibiotic prophylactic strategy for catheter-associated urinary tract infection in patients with long-term catheterization.","Patient with long-term indwelling Foley catheter with at least one documented catheter-associated urinary tract infection episode or hospital admission for suspected urinary tract infection in the preceding 6 months.",[42],{"label":43,"type":35,"description":44,"interventionNames":45},"Uromune","Standard treatment course: oral bacterial immunotherapy (Sublingual Vaccine Uromune) MV140",[46],"Drug: Uromune",[48],{"type":49,"name":43,"description":50,"armGroupLabels":51,"otherNames":35},"DRUG","Oral bacterial immunotherapy (Sublingual Vaccine Uromune) MV140",[43],[53],{"name":54,"role":55,"phone":56,"phoneExt":35,"email":57},"Alex Qinyang LIU, MBBS, MSc, FRCSEd","CONTACT","+852 35052625","alexliu@surgery.cuhk.edu.hk",[59],{"facility":60,"status":35,"city":61,"state":35,"zip":35,"country":61,"countryCode":62,"cosmosGeoPoint":63,"geoPoint":68,"contacts":69},"Prince of Wales Hospital","Hong Kong","HK",{"type":64,"coordinates":65},"Point",[66,67],114.17469,22.27832,{"lat":67,"lon":66},[70],{"name":54,"role":55,"phone":56,"phoneExt":35,"email":57},{"type":72,"investigatorFullName":73,"investigatorTitle":74,"investigatorAffiliation":5,"oldNameTitle":35,"oldOrganization":35},"PRINCIPAL_INVESTIGATOR","Alex Qinyang Liu","Assistant Professor","100659868","evaluate-of-the-use-of-uromune-as-a-potential-non-antibiotic-prophylactic-strategy-for-catheter-associated-urinary-tract-infection-in-patients-with-long-term-catheterization-100659868",false,"NCT07869992","Evaluate of the Use of Uromune as a Potential Non-antibiotic Prophylactic Strategy for Catheter-associated Urinary Tract Infection in Patients With Long-term Catheterization.","Oral Bacterial Immunotherapy (Uromune) in Long-term Indwelling Foley Catheter Patients: a Self-controlled Pilot Study for Prevention of Catheter-associated Urinary Tract Infection (CAUTI) With Microbiome and Immune Correlates","Inclusion Criteria:\n\n* Adults aged ≥18 years\n* Long-term indwelling Foley catheter (≥4 weeks prior to enrolment)\n* Expected to remain catheterized for ≥6 months\n* At least one documented CAUTI episode or hospital admission for suspected UTI in the preceding 6 months\n\nExclusion Criteria:\n\n* Planned catheter removal within 6 months\n* Ongoing systemic infection at enrolment\n* Immunosuppression state including:\n\n  \\- Primary immunodeficiency - Systemic immunosuppressive therapy e.g. steroid, chemotherapy, biologics, or immunosuppressants - Known HIV carrier or AIDS patient\n* Known hypersensitivity to components of Uromune","ALL","18 Years",{"count":85,"type":86},30,"ESTIMATED","12 Months","OBSERVATIONAL","A self-controlled pilot study to evaluate the use of oral bacterial immunotherapy for prevention of catheter-associated urinary tract infection.",[91],"Catheter-Associated Urinary Tract Infections (CAUTIs)",[93,43],"Oral bacterial immunotherapy","NOT_YET_RECRUITING","2026-10-06",{"date":97,"type":98},"2026-10-13","ACTUAL",{"date":100,"type":86},"2026-10-30",{"date":102,"type":86},"2027-12-31",{"name":5,"class":6},1]